1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. Company
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
Delayed Nasdaq  -  05/26 04:00:00 pm EDT
5.070 USD   +9.50%
04:06pExagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
GL
04:05pExagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Exagen Inc.
Exagen Inc. is a commercial-stage life sciences company. The Company offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The Company develops and commercialize testing products under the brand name AVISE. Its products include AVISE CTD, AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE PC4d, AVISE SLE Monitor and AVISE MTX. The Company's lead testing product AVISE enables diagnosis for patients with symptoms of connective tissue diseases (CTD) and Systemic lupus erythematosus (SLE). The Company’s AVISE brand allows for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis (RA). The Company’s product portfolio integrates proprietary CB-CAPs technology, which is a stable and reliable method for differentially diagnosing systemic lupus erythematosus.

Number of employees : 222 people.
Sales per Business
20202021Delta
Healthcare Insurers22.4653.5%27.5056.9% +22.46%
Client5.1112.2%9.2919.2% +81.8%
Government8.4520.1%9.2219.1% +9.18%
Janssen (SIMPONI)5.1312.2%1.202.5% -76.6%
Other0.842%1.092.3% +30.5%
USD in Million
Sales per region
20202021Delta
United States41.98100%48.30100% +15.07%
USD in Million
Managers
Name Title Age Since
Fortunato Ron Rocca President, Chief Executive Officer & Director 59 2011
Kamal Adawi Chief Financial Officer & Secretary 42 -
Debra Jeske Zack, Dr. Chief Medical Officer 64 2020
Anja Kammesheidt, Dr. Chief Scientific Officer - 2020
Ming-Chou Lee Chief Technology Officer - 2021
Mark Hazeltine Chief Operating Officer 47 2021
Ryan Douglas Head-Investor Relations - -
John Wegener Senior Vice President-Sales & Marketing 52 -
Jon Buncab National Director-Managed Markets - -
Members of the board
Name Title Age Since
Brian P. Birk Chairman 61 -
Ebetuel Pallares, Dr. Independent Director 47 2012
James Tullis Independent Director 73 2015
Tina Nova Independent Director 67 2019
Bruce C. Robertson, Dr. Independent Director 58 2019
Wendy S. Johnson Independent Director 69 2020
Franklin Michael Stokes Independent Director 51 2021
Ana Hooker Independent Director 55 2021
Fortunato Ron Rocca President, Chief Executive Officer & Director 59 2011
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 16,256,051 9,573,642 58.9% 0 0.0% 58.9%
Shareholders
NameEquities%
Sun Mountain Capital LLC 2,308,958 14.2%
H.I.G. Capital LLC (Private Equity) 1,696,252 10.5%
Tullis Health Investors, Inc. 1,537,020 9.47%
Cowen & Co. LLC 1,384,631 8.53%
Stonepine Capital Management LLC 1,121,040 6.91%
Wasatch Advisors, Inc. 1,089,312 6.71%
BMO Asset Management, Inc. 1,015,612 6.26%
Hunt Cos., Inc. 1,011,324 6.23%
RTW Investments LP 990,143 6.10%
Farallon Capital Management LLC 577,699 3.56%
Company contact information
Exagen, Inc.
1261 Liberty Way
Suite C
Vista, CA 92081

Phone : +1.760.560.1501
Web : http://www.exagen.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Exagen Inc.